| Names | |
|---|---|
| Preferred IUPAC name (1S,9S)-9-{[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider |
|
| DrugBank |
|
| ECHA InfoCard | 100.168.764 |
| KEGG |
|
| UNII | |
| |
| |
| Properties | |
| C22H31N3O5 | |
| Molar mass | 417.506 g·mol−1 |
| logP | 2.212 |
| Acidity (pKa) | 2.285 |
| Basicity (pKb) | 11.712 |
| Pharmacology | |
| C09AA08 (WHO) | |
| Oral | |
| Legal status | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Cilazapril is anangiotensin-converting enzyme inhibitor (ACE inhibitor) used for the treatment ofhypertension andcongestive heart failure.[1][2]
It was patented in 1982 and approved for medical use in 1990.[3]
Of the eight possiblestereoisomers, only the all-(S)-form is medically viable.[citation needed]
It is branded as Dynorm, Inhibace, Vascace and many other names in various countries. None of these are available in the United States as of May 2010.[4]
Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byadding missing information. |